IL2RA and neoplasm: The manipulation of Treg cells is a crucial component of tumour immune surveillance and is based on numerous approaches, including depletion, reducing survival or suppressing the function of Treg cells with tyrosine kinase inhibitors, low-dose cyclophosphamide and paclitaxel, as well as checkpoint inhibitors and IL-2Rα-targeting agents2.